Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
Rhea-AI Summary
Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET. The presentation is virtual and Mr. Levy is available for one‑on‑one investor meetings scheduled through Sidoti representatives.
Positive
- None.
Negative
- None.
News Market Reaction – DRTSW
On the day this news was published, DRTSW declined 2.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DRTSW gained 3.26% while warrant peers were mixed: KTTAW +7.92%, CELUW +16%, but BCTXW -50% and LIXTW -37.22%. With no peers in the momentum scanner and no same-day peer headlines, this move appears stock-specific rather than a coordinated sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Full-year results | Positive | +5.2% | Reported 2025 results with cash balance, net loss and pipeline progress. |
| Feb 24 | Regulatory approval | Positive | +1.7% | Received Japanese marketing approval for Alpha DaRT in head and neck cancer. |
| Jan 29 | Corporate roadmap | Positive | -9.1% | Outlined five concurrent U.S. trials and key 2026 value-driving milestones. |
| Jan 06 | Clinical data update | Positive | +9.3% | Reported positive PDAC study results with meaningful ORR and DCR at ASCO GI. |
| Jan 05 | Regulatory submission | Positive | +16.2% | Submitted first PMA module to FDA for recurrent cSCC using modular pathway. |
Recent fundamentally positive catalysts (regulatory wins, clinical data, PMA progress) most often saw positive price reactions, with one notable selloff after a bullish shareholder letter.
Over recent months, Alpha Tau has reported multiple catalysts: submission of the first PMA module for Alpha DaRT® in recurrent cSCC with Breakthrough Device Designation across several indications on Jan 05, 2026; positive pancreatic PDAC data with ORR up to 23% and DCR up to 87% across 32 patients at ASCO GI on Jan 06; a shareholder letter outlining five concurrent U.S. trials and manufacturing scale-up on Jan 29; Japanese marketing approval requiring a 66-patient post‑market study on Feb 24; and full-year 2025 results with $76.9M cash and a $42.6M net loss on Mar 09. Today’s conference appearance fits a pattern of active investor outreach following substantial clinical and regulatory progress.
Regulatory & Risk Context
The company has an active F-3 shelf registration filed on 2025-06-23 and effective through 2028-06-23, with reported usage_count of 0, indicating no disclosed takedowns from this shelf to date.
Market Pulse Summary
This announcement highlights Alpha Tau’s participation in a virtual small-cap conference on March 18, 2026, with a 30‑minute presentation and 1x1 investor meetings. In context, the company recently reported Japanese marketing approval requiring a 66-patient surveillance study, positive PDAC data with ORR up to 23%, and full‑year 2025 results showing $76.9M cash and a $42.6M net loss. Investors would likely focus on how management updates these clinical, regulatory, and cash runway developments during the event.
AI-generated analysis. Not financial advice.
JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026.
| Event: | Sidoti Virtual Small Cap Conference |
| Format: | Company Presentation |
| Date: | March 18, 2026 |
| Time: | 10:00 – 10:30AM ET |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
FAQ
When will Alpha Tau (DRTS) present at the Sidoti Virtual Small Cap Conference?
How can investors meet Alpha Tau CFO Raphi Levy at the Sidoti conference (DRTS)?
Where can I watch Alpha Tau's (DRTS) presentation at the Sidoti Virtual Small Cap Conference?
What topics will Alpha Tau (DRTS) cover in the Sidoti conference presentation?
Is Alpha Tau's Sidoti presentation (DRTS) open to the public or by appointment?
